Core Viewpoint - Xingyu Co., Ltd. (601799) is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international strategy and diversify financing channels for high-quality development [1] Group 1: H-Share Listing - The company is currently discussing the specifics of the H-share issuance with relevant intermediaries, and the details are yet to be finalized [1] - The H-share listing will not result in changes to the controlling shareholder or actual controller of the company [1] Group 2: Business Overview - Xingyu Co., Ltd. specializes in the design, development, manufacturing, and sales of automotive lighting products, including front and rear lights and interior/exterior decorative lights [1] - The company has entered the supply chains of various European, Japanese, American, and Chinese domestic automobile brands [1] - The company has increased its efforts in expanding overseas markets, establishing a factory in Serbia, and has seen a 49% year-on-year increase in overseas revenue, reaching 500 million yuan in 2024 [1] Group 3: Financial Performance - In the first three quarters of this year, the company achieved a revenue of 10.71 billion yuan, a year-on-year increase of 16.09%, and a net profit attributable to shareholders of 1.141 billion yuan, up 16.76% year-on-year [2] Group 4: New Ventures and Collaborations - In October, the company established Changzhou Xingyu Intelligent Robot Co., Ltd. with a registered capital of 100 million yuan, entering the robotics field [2] - The company signed a strategic cooperation agreement with Jieke Robot Co., Ltd. to collaborate in three main areas: embodied intelligent robot innovation, smart manufacturing upgrades, and industry chain collaboration [2] - The cooperation will focus on joint innovation in embodied intelligence, integration of robots with AI algorithms for innovative applications in automotive parts, and sharing technology standards and scene data to promote domestic core components and innovative applications [2]

①濮阳开州投资集团拟发行8亿元公司债，获上交所通过； ②因涉嫌内幕交易等，贵州百灵实控人姜伟被证监会立案； 实习编辑:金怡杉 | 审核:李震 | 监审:古筝 ③星宇股份筹划发行H股股票并在港交所上市； ④德固特终止筹划重大资产重组事项； ⑤国发股份董事长姜烨因个人原因辞任，辞任后不再担任该公司及控股子公司任何职务； ⑥山西汾酒股东华创鑫睿减持计划实施完毕，共减持1620万股该公司股份，占该公司总股本的1.33%； ⑦唯赛勃控股股东香港唯赛勃拟减持不超过520万股该公司股份，即不超过该公司总股本的2.99%； ⑧腾景科技股东福建华兴拟减持不超过254.03万股该公司股份，即不超过该公司总股本的1.96%； ⑨长盈通董事柳祎因个人原因辞职，辞职后不再担任该公司任何职务； ⑩因近期市场波动较大，开滦集团决定取消发行"25开滦MTN006"。 #成为立方风控鸟会员，尊享直播版风控服务# ...

Group 1 - Dongfang Electric announced that three executives plan to reduce their holdings by a total of no more than 30,000 shares due to personal financial needs [1] - Yahu Pharmaceutical's APL-1401 clinical trial data was presented at the 19th European Colorectal Congress, indicating progress in treating moderate to severe ulcerative colitis [1] - Guizhou Bai Ling's actual controller is under investigation by the China Securities Regulatory Commission for insider trading and information disclosure violations [3] Group 2 - Bairen Medical's ePTFE pericardial membrane product has been approved for registration, ending the reliance on imports for this product in the domestic market [4] - Qianxin received approval for a total of 2 billion yuan in technology innovation bonds, with plans to issue medium-term notes and short-term financing bonds [6] - Tengjing Technology's shareholder plans to reduce holdings by no more than 1.96% of the company's shares [7] Group 3 - Yuntianhua's subsidiary is required to pay 386 million yuan in overdue taxes and penalties, which will impact the company's net profit for 2025 [8] - Jianyou Pharmaceutical's propofol emulsion injection has received FDA approval in the United States [9] - Suzhou Gaoxin successfully acquired land use rights for a residential project for 360 million yuan [9] Group 4 - Chalco International's subsidiary won a bid for a 3.03 billion yuan electrolytic aluminum project [11] - Tai Long Pharmaceutical's stock will continue to be suspended due to potential changes in control as the major shareholder is planning a share transfer [12] - Qianli Technology reported a 63.44% year-on-year increase in automobile sales for November, although new energy vehicle sales decreased by 43.98% [13] Group 5 - Fosun Pharma's innovative drug FXS0887 has received approval for a Phase I clinical trial for advanced malignant solid tumors [14] - Guoen Co. has obtained approval for a project to produce 20,000 square meters of aviation-grade acrylic glass, with a total investment of 560 million yuan [15] - Guofa Co.'s chairman resigned due to personal reasons [17] Group 6 - Shanghai Construction won a bid for a state-owned construction land use right for 264 million yuan [18] - Weixin Kang's subsidiary received approval for a clinical trial of lidocaine cream for local anesthesia [20] - Sanxing Medical's subsidiary is a candidate for a 152 million yuan transformer procurement project for the State Grid [20] Group 7 - People's Daily announced the resignation of its president due to work changes, while retaining other leadership roles [21] - Beibu Gulf Port reported a 0.29% year-on-year increase in cargo throughput for November [22] - Chongqing Construction won three engineering projects with a total value of approximately 2.773 billion yuan [23] Group 8 - Xingyu Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange [24] - Huajian Group signed a design contract worth 160 million yuan for a comprehensive project [25] - Wankai New Materials plans to invest 350 million yuan in a technical transformation project for producing 100,000 tons of adipic acid [26] Group 9 - Kaipuyun received a government subsidy of 18 million yuan, which is 87.43% of its net profit for the last audited fiscal year [28] - Ningbo Port expects a 10.8% year-on-year increase in container throughput for November [30] - An Cai High-Tech plans to invest 498 million yuan to upgrade its photovoltaic glass production line [32] Group 10 - Shunhao Co. stated that its existing business has not generated synergies with the rail business, which faces various risks [34] - Yihualu plans to publicly transfer 35% of its stake in Liaoyun Company [35] - ST Wanfang's shareholder plans to reduce holdings by no more than 3% of the company's shares [36] Group 11 - Youyou Food's shareholder plans to reduce holdings by no more than 110,000 shares [38] - Hengtong Optic-Electric's incentive fund has spent 49.98 million yuan to purchase company shares [41] - Zoli Pharmaceutical plans to issue convertible bonds to raise no more than 1.556 billion yuan for various projects [42]

证券简称：星宇股份 证券代码：601799 编号：2025-036 常州星宇车灯股份有限公司（以下简称"公司"）为深化国际化战略布局， 提升公司品牌国际影响力，积极借助国际资本市场拓展多元化融资渠道，助力公 司高质量发展，正在筹划发行境外股份（H 股）并在香港联合交易所有限公司（以 下简称"香港联交所"）上市事宜（以下简称"本次 H 股上市"）。公司正在与相 关中介机构就本次 H 股上市的具体推进工作进行商讨，相关细节尚未确定，本 次 H 股上市不会导致公司控股股东和实际控制人发生变化。 常州星宇车灯股份有限公司 关于筹划发行 H 股股票并在香港联合交易所有限公司上市 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上海证券交易 所股票上市规则》、《境内企业境外发行证券和上市管理试行办法》、《香港联合交 易所有限公司证券上市规则》等相关规定，待确定具体方案后，本次 H 股上市 工作尚需提交公司董事会、股东会审议通过，并经过中国证券监督管理委员会备 案和香港 ...

智通财经APP讯，星宇股份(601799.SH)发布公告，公司为深化国际化战略布局，提升公司品牌国际影 响力，积极借助国际资本市场拓展多元化融资渠道，助力公司高质量发展，正在筹划发行境外股份(H 股)并在香港联交所上市事宜。公司正在与相关中介机构就本次H股上市的具体推进工作进行商讨，相 关细节尚未确定，本次H股上市不会导致公司控股股东和实际控制人发生变化。 ...

Core Viewpoint - The company is planning to issue overseas shares (H-shares) and list on the Hong Kong Stock Exchange to enhance its international strategy and brand influence [1] Group 1 - The company aims to deepen its international strategic layout and improve its brand's international influence [1] - The company is actively leveraging international capital markets to diversify its financing channels [1] - The H-share listing will not result in changes to the company's controlling shareholder or actual controller [1] Group 2 - The company is currently in discussions with relevant intermediaries regarding the specific progress of the H-share listing [1] - Details of the H-share listing are yet to be determined [1]

格隆汇12月3日丨星宇股份(601799.SH)公布，公司为深化国际化战略布局，提升公司品牌国际影响力， 积极借助国际资本市场拓展多元化融资渠道，助力公司高质量发展，正在筹划发行境外股份(H股)并在 香港联合交易所有限公司(以下简称"香港联交所")上市事宜(以下简称"本次H股上市")。公司正在与相关 中介机构就本次H股上市的具体推进工作进行商讨，相关细节尚未确定，本次H股上市不会导致公司控 股股东和实际控制人发生变化。 ...

星宇股份公告，公司正在筹划发行境外股份（H股）并在香港联合交易所有限公司上市。公司正在与相 关中介机构就本次H股上市的具体推进工作进行商讨，相关细节尚未确定。本次H股上市不会导致公司 控股股东和实际控制人发生变化。 ...

证券简称：星宇股份 证券代码：601799 编号：2025-035 2025 年第三季度业绩说明会预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可以在2025年12月2日上午8:00至下午16:00通过公告后附的电话、邮 件等联系公司，提出所关注的问题，公司将在说明会上选择投资者普遍关注的问 题进行回答。 公司已于2025年10月30日披露了《星宇股份2025年第三季度报告》，为便于 广大投资者更全面深入地了解公司2025年第三季度的经营成果及财务状况，公司 决定于2025年12月3日通过网络文字互动方式召开"星宇股份2025年第三季度业 绩说明会"。 一、说明会类型 本次业绩说明会以网络文字互动方式召开，公司将针对2025年第三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 召开时间：2025年12月3日（星期三）上午10:00-11:00 召开地点：上海证券报·中国证券网（https:// ...

Core Viewpoint - Xingyu Co., Ltd. has experienced a decline in stock price and trading activity, with a notable drop in market capitalization and net outflow of funds, indicating potential investor concerns [1][2]. Financial Performance - For the period from January to September 2025, Xingyu Co., Ltd. achieved a revenue of 10.71 billion yuan, representing a year-on-year growth of 16.09% [2]. - The net profit attributable to shareholders for the same period was 1.14 billion yuan, reflecting a year-on-year increase of 16.76% [2]. - Cumulative cash dividends since the company's A-share listing amount to 3.71 billion yuan, with 1.14 billion yuan distributed over the past three years [2]. Stock Market Activity - As of November 27, the stock price of Xingyu Co., Ltd. was 120.91 yuan per share, with a market capitalization of 34.54 billion yuan [1]. - The stock has declined by 8.39% year-to-date, with a 1.27% drop over the last five trading days and a 6.16% decline over the past 20 days [1]. - The company experienced a net outflow of 21.16 million yuan in principal funds, with significant selling pressure observed [1]. Shareholder Composition - As of September 30, 2025, the number of shareholders increased by 19.06% to 13,800, while the average circulating shares per person decreased by 16.01% to 20,772 shares [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 36.86 million shares, an increase of 12.72 million shares from the previous period [2]. - Other notable shareholders include various ETFs and mutual funds, with some experiencing reductions in their holdings [2].